Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014;41:11–20.
Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, et al. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis. BJU Int. 2017;120:197–203.
Alves F, Alves VHP, Do Carmo SJC, Neves ACB, Silva M, Abrunhosa AJ. Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets. Mod. Phys. Lett. A. 2017;32:1740013.
Alves V, do Carmo S, Alves F, Abrunhosa A. Automated Purification of Radiometals Produced by Liquid Targets. Instruments. 2018;2:17.
Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics. 2012;2:437–47.
Blower JE, Cooper MS, Imberti C, Ma MT, Marshall C, Young JD, et al. The Radiopharmaceutical Chemistry of the Radionuclides of Gallium and Indium. In: Radiopharmaceutical Chemistry by Lewis J, Windhorst A, Zeglis B (Eds). Springer; 2019. p. 255–71.
Boschi A, Martini P, Costa V, Pagnoni A, Uccelli L, Santini C, et al. Interdisciplinary Tasks in the Cyclotron Production of Radiometals for Medical Applications. The Case of 47Sc as Example. Molecules. 2019;24:1–14.
Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J. Nucl. Med. 2018;59:789–94.
Cutler CS, Minoshima S. Shortage of Germanium68/gallium68 generators in the United States [Internet]. 2018; Available from: https://s3.amazonaws.com/rdcms-snmmi/files/production/public/Ga68%20shortage%20letter.pdf. Accessed 12-Aug-2020.
Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 2014;7:779–96.
Engle JW, Lopez-Rodriguez V, Gaspar-Carcamo RE, Valdovinos HF, Valle-Gonzalez M, Trejo-Ballado F, et al. Very high specific activity 66/68Ga from zinc targets for PET. Appl. Radiat. Isot. 2012;70:1792–6.
Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Basic Original Report Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract. Radiat. Oncol. 2018;8:28–39.
Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer. J. Nucl. Med. 2017;58:1196–200.
Gallium (68Ga) Chloride (accelerator produced) solution for radiolabelling. European Pharmacopoeia. 2020;10(Suppl. 10.3):4864-4865.
International Atomic Energy Agency. Gallium-68 Cyclotron Production. IAEA-TECDOC-1863. IAEA, Vienna; 2019.
Gourni E, Demmer O, Schottelius M, D’Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent. J. Nucl. Med. 2011;52:1803–10.
Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis. J. Nucl. Med. 2017;58:1452–8.
Graves SA, Engle JW, Eriksson TE, Gagnon K. Dosimetry of cyclotron-produced [68Ga]Ga-PSMA-11, [68Ga]Ga-DOTA-TATE, and [68Ga]Ga-DOTA-TOC. J. Nucl. Med. 2018;59(Suppl. 1):1003.
Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease. J. Nucl. Med. 2016;57:248–51.
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146–56.
Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J. Nucl. Med. 2017;58:1956–61.
Jackson IM, Scott PJH, Thompson S. Clinical Applications of Radiolabeled Peptides for PET. Semin. Nucl. Med. 2017;47:493-523.
Jensen M, Clark JC. Direct production of Ga-68 from proton bombardment of concentrated aqueous solutions of [Zn-68] Zinc Chloride. In The 13th International Workshop on Targetry and Target Chemistry Proceedings by Horoun S, Givskov and Jensen M (Eds). Risø DTU, National Laboratory for Sustainable Energy, Technical University of Denmark. Roskilde. 2011; 288-292. Available online: https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/006/43006750.pdf. Accessed 12-Aug-2020.
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests efficacy regarding duration of tumor control. J. Nucl. Med. 2018;59:795–802.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J. Nucl. Med. 2019;60:801–5.
Lenzo N, Meyrick D, Turner J, Lenzo NP, Meyrick D, Turner JH. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics.; 2018;8:16.
Lin M, Waligorski GJ, Lepera CG. Production of curie quantities of 68Ga with a medical cyclotron via the 68Zn(p,n)68Ga reaction. Appl. Radiat. Isot. 2018;133:1–3.
Lowe VJ, Kwon ED. PET in Prostate Cancer: A Focus on C-11 Choline. Pathways Clin. Trials Netw. Newsl. 2015;5:1-4. [Internet] Available from: http://s3.amazonaws.com/rdcms-snmmi/files/production/public/images/Publications/Jan%202015%20Pathways_web.pdf. Accessed 12-Aug-2020.
Martiniova L, De Palatis L, Etchebehere E, Ravizzini G. Gallium-68 in Medical Imaging. Curr. Radiopharm. 2016;9:187–207.
McCormick B, Mahmoud A, Williams S, Davis J. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J. Urol. 2019;35:6–17.
Mossine A V., Tanzey SS, Brooks AF, Makaravage KJ, Ichiishi N, Miller JM, et al. Synthesis of high-molar-activity [18F]6-fluoro-l-DOPA suitable for human use via Cu-mediated fluorination of a BPin precursor. Nat. Protoc. 2020;15:1742–59.
Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WAP. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug. Chem. 2012;23:1712–7.
Nair M, Happel S, Eriksson T, Pandey M, DeGrado T, Gagnon K. Cyclotron production and automated new 2-column processing of [68Ga]GaCl3. Eur J Nucl Med Mol Imaging . 2017;44(Suppl 2):S119–956.
Oehlke E, Hoehr C, Hou X, Hanemaayer V, Zeisler S, Adam MJ, et al. Production of Y-86 and other radiometals for research purposes using a solution target system. Nucl. Med. Biol. 2015;42:842–9.
Pandey MK, Byrne JF, Jiang H, Packard AB, DeGrado TR. Cyclotron production of 68Ga via the 68Zn(p,n)68Ga reaction in aqueous solution. Am. J. Nucl. Med. Mol. Imaging. 2014;4:303–10.
Pandey MK, Byrne JF, Schlasner KN, Schmit NR, DeGrado TR. Cyclotron production of 68Ga in a liquid target: Effects of solution composition and irradiation parameters. Nucl. Med. Biol. 2019;74/75:49-55.
Pandey MK, DeGrado TR. Rapid Isolation of Cyclotron-Produced Gallium-68. 2019; WO2018039662.
Prostate Cancer: Statistics [Internet]. 2020; Available from: https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed 12-August-2020.
Riga S, Cicoria G, Pancaldi D, Zagni F, Vichi S, Dassenno M, et al. Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. Phys. Medica. 2018;55:116–26.
Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study. J. Nucl. Med. 2018;59:82–8.
Ruangma A, Kijprayoon S, Ngokpol S. PSMA for PET imaging of prostate cancer. Bangkok Med. J. 2018;14:95–100.
Sadeghi M, Kakavand T, Rajabifar S, Mokhtari L, Rahimi-Nezhad A. Cyclotron production of 68Ga via proton-induced reaction on 68Zn target. Nukleonika. 2009;54:25–8.
Schweinsberg C, Johayem A, Llamazares A, Gagnon K. The first curie-quantity production of [68Ga]Ga-PSMA-HBED-CC. J. Label. Compd. Radiopharm. 2019;62(S1):P121.
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:92–101.
Shao X, Hoareau R, Runkle AC, Tluczek LJM, Hockley BG, Henderson BD, et al. Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro. J. Label. Compd. Radiopharm. 2011;54:819–38.
Shao X, Hockley BG, El Hoareau R, Schnau PL, Scott PJH. Fully automated preparation of [11C]choline and [18F]fluoromethylcholine using TracerLab synthesis modules and facilitated quality control using analytical HPLC. Appl. Radiat. Isot. 2010;69:403–9.
Smith DL, Breeman WAP, Sims-Mourtada J. The untapped potential of Gallium 68-PET: The next wave of 68Ga-agents. Appl. Radiat. Isot. Pergamon; 2013;76:14–23.
Tolmachev V, Lundqvist H. Rapid separation of gallium from zinc targets by thermal diffusion. Appl. Radiat. Isot. 1996;47:297–9.
Velikyan I. Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation. Contrast Media Mol. Imaging. Hindawi; 2018;2018:1–24.
Zeisler S, Limoges A, Kumlin J, Siikanen J, Hoehr C. Fused Zinc Target for the Production of Gallium Radioisotopes. Instruments. 2019;3:10.
USP 71 Microbiological Tests/Sterility Tests. United States Pharmacopeial Conv. 2012.